EnChannel Medical to Acquire Acutus Medical AcQMap™ Electrophysiology Assets
"This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision," said Jun Feng, CEO of EnChannel Medical. "By building on prior advancements and leveraging our proprietary technologies, we are shaping the future of persistent AF diagnosis and treatment."
Contact and Non-Contact Mapping in Perspective
Conventional contact mapping systems sequentially collect electrical signals by making physical contact with many small regions of cardiac tissue, generating regional maps of electrical activity over numerous beats that are gradually assembled into a composite view across the chamber surface. While effective for regular rhythms, it is time-consuming, and it cannot capture the full dynamics of irregular activation patterns, such as in AF, often averaging out critical details and reducing mapping accuracy and specificity.
In contrast, non-contact mapping (NCM) reconstructs full-chamber electrical activity from cardiac signals sensed by numerous electrodes distributed within the atrial chamber cavity. NCM delivers a comprehensive, single-beat depiction of activation over the entire atrial chamber at every instance of time. This approach significantly improves mapping efficiency and preserves the dynamic patterns of both regular and complex, irregular rhythms, including AF.
Acutus' AcQMap™ technology is a second-generation NCM platform that advanced beyond the first-generation voltage-to-voltage mapping (pioneered by Endocardial Solutions – now part of Abbott), and delivered improved spatial resolution and accuracy, using voltage-to-charge-density mapping.
Advancing the Frontier of Non-Contact Mapping
EnChannel's propriety Action Potential Mapping offers a third-generation breakthrough in NCM technology, with accurate reconstruction of both depolarization and repolarization dynamics. This fulfills a biophysical unmet need that remains in conventional mapping, which cannot address repolarization. Action Potential Mapping therefore approaches the real nature of cardiac conduction and enables comprehensive understanding of the mechanisms that initiate and maintain AF – laying the groundwork for precise, individualized treatment of persistent AF.
"Many of us at EnChannel had essential roles in developing all three generations of non-contact mapping," said Graydon Beatty, CSO of EnChannel Medical. "Each generation informed and enabled the next one; from reproduction of the cardiac signal in the first; to resolving the physical electric source of the signal in the second; and now culminating in reconstruction of the physiologic action potential in the third, revealing the actual nature of cardiac conduction dynamics. This acquisition unites our history of requisite methods and resources across the generations, and advances a hybrid workflow of all modes of navigation, mapping, and visualization. We are poised and resolved to establish an electrophysiology ecosystem that uncovers the mechanisms of AF, optimizes patient-specific treatment, and improves clinical outcomes in persistent AF."
About EnChannel Medical
Founded in 2020 by a team of seasoned electrophysiology innovators from both the United States and China, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions.
For more information, visit http://www.enchannel.com and follow us on LinkedIn.
EnChannel's mapping and ablation products are investigational devices and are limited by federal (or United States) law to investigational use.
Media Contact
Bradley Wegrzynowicz
(610) 462-0197
[email protected]
SOURCE EnChannel Medical Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
TORONTO, July 2, 2025 /CNW/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization. This approval marks a key milestone for Apotex, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the Company's commitment to expand its biologics portfolio and execution of its Journey of Health strategy. "With Aflivu, we're expanding affordable treatment options for Canadians affected by retinal diseases," said Raymond Shelley, President, Apotex Canada. "Apotex continues to deliver innovative, patient-focused solutions across our growing portfolio of brands, biosimilars, generics and consumer health products." "The approval of Aflivu represents a positive advancement in ophthalmic care," said Dr. Bernard R. Hurley, BSc, MD, FRCSC, Assistant Professor at the University of Ottawa Eye Institute. "Biosimilars, supported by clinicians, regulators, and manufacturers, have the potential to transform the treatment landscape for retinal diseases, preserving vision and providing quality, cost-effective care for countless Canadians." "In clinical practice, having access to a broader range of therapeutic options can empower physicians to tailor care to individual patients' needs," said Dr. Ghassan Cordahi, MD, FACS, Assistant Clinical Professor, Faculty of Medicine, Department of Ophthalmology, Université de Montréal. "Aflibercept has been a cornerstone in managing retinal diseases, and the introduction of Aflivu offers a more affordable alternative without compromising quality." Aflivu joins Apotex's successful biosimilar portfolio, which includes Grastofil® (filgrastim), Lapelga® (pegfilgrastim), and Bambevi® (bevacizumab). About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Cision Canada
3 hours ago
- Cision Canada
IKEA Richmond and Richmond Food Bank partner to support local families for Back to School
Double the impact: IKEA Richmond will match back to school essentials donated by customers. RICHMOND, BC, July 2, 2025 /CNW/ - IKEA Richmond is teaming up with the Richmond Food Bank to help create a better everyday life for children and youth in the community heading back to school without proper essentials, such as lunch bags, reusable food containers, water bottles and other beverage containers. With 18 percent of Richmond Food Bank clients being school-aged children, this initiative aims to ensure every child returns to school nourished, confident, and ready to learn. From July 7 to August 10, 2025, IKEA Richmond will collect back to school essentials that help children bring nutritious lunches and snacks to school. To amplify community support, IKEA Richmond will match the retail value of donated IKEA "Back to School" essentials up to a maximum of $5,000. The rising cost of living has made it increasingly difficult for many families to afford both food and school supplies. For families relying on the food bank, the added burden of back-to-school expenses can be overwhelming. "At IKEA, our vision is to create a better everyday life for the many people," says Maria Valley, Communications Responsible at IKEA Richmond. "We believe every child deserves the opportunity to thrive at school, and that starts with being well-fed and well-prepared. By working together with the Richmond Food Bank, we're helping families stretch their budgets further while supporting children's health and education." How the community can make a difference. Double the impact. For every IKEA "Back to School" item donated at IKEA Richmond during the campaign period, IKEA Richmond will match with similar products up to a maximum of $5000 retail value. A list of suggested products including lunch bags, reusable food containers, water bottles, beverage containers and more can be found by visiting Donate non-IKEA essentials. IKEA Richmond will support as a drop-off location for non-perishable food items such as canned protein (chicken, turkey, meat, fish, beans and chickpeas), canned vegetables and fruits, rice and pasta. Spread the word. Share the campaign with friends, family, and local organization to maximize the community impact. "We're seeing more families than ever before turning to us for help," says Hajira Hussain, Executive Director of the Richmond Food Bank. "With school-aged children making up nearly one-fifth of our clients, this initiative couldn't come at a better time. We're grateful to IKEA Richmond for stepping up to support our community in such a meaningful way." This partnership is tied to the IKEA Neighborhoods initiative, IKEA Canada's broader commitment to affordability and community support. IKEA Neighborhoods is about creating positive social impact for the many people, by using our business capabilities such as home furnishing expertise, our product range, our IKEA stores and the IKEA co-workers. This approach contributes to local communities to be fairer, more inclusive and more sustainable neighborhoods. At IKEA, creating positive social impact is good for business and for society. This initiative relies on the expertise of community partners, such as Richmond Food Bank, to help identify the neighborhood's most critical issues and to co-create impactful solutions. Donations of IKEA and non-IKEA back to school essentials for Richmond Food Bank are accepted at IKEA Richmond, 3320 Jacombs Road, Richmond, BC V6V 1Z6 during store opening hours from July 7 – August 10, 2025. Every donation, no matter how small, can make a big difference for a family in the community. For more details, visit ABOUT RICHMOND FOOD BANK The Richmond Food Bank Society is a charitable organization and a member of Food Banks BC and Food Banks Canada. Their mission is to provide food assistance, advocacy and related support to community members in need, with a vision for a caring community where no one goes hungry. The Richmond Food Bank gives health and nutritionally-balanced food to more than 2,800 people in average week, providing Richmond resident with healthy food choices and connecting their clients to services that address the route causes of poverty. For more information, visit ABOUT IKEA CANADA Founded in 1943 in Sweden, IKEA is a leading home furnishing retailer, offering a wide range of well-designed, functional home furnishing products at prices so low that as many people as possible can afford them. IKEA Canada is part of Ingka Group which operates 574 IKEA stores, shops and planning studios in 31 countries, including 16 in Canada. Last year, IKEA Canada welcomed 32.6 million visitors to its stores and 162.6 million visitors to IKEA Canada operates business through the IKEA vision - to create a better everyday life for the many people and does so through its local community efforts and sustainability initiatives. For more information on IKEA Canada, please visit
Cision Canada
3 hours ago
- Cision Canada
TRUBAR INC. ANNOUNCES SALE OF PERSONAL CARE PRODUCT LINE
VANCOUVER, BC, July 2, 2025 /CNW/ - TRUBAR Inc. (formerly, Simply Better Brands Corp.) (" TRUBAR" or the " Company") (TSXV: TRBR) (OTCQX: TRBRF), a better-for-you snacking company focused on delivering high-quality, plant-based protein products with exceptional taste and made with clean, recognizable ingredients, is pleased to announce that NO BS Life, LLC, a subsidiary of the Company, has completed the sale of the assets of NO BS Life, LLC comprising its personal care product line to an arm's length third party buyer. In connection with the Transaction, NO BS Life, LLC intends to satisfy its outstanding obligations and distribute any remaining proceeds of the Transaction (after payment of, among other things, transaction costs) to the members of NO BS Life, LLC. Erica Groussman comments "The sale of NO B.S.'s business marks a continuation of our efforts to align our corporate identity with the brand driving our growth, TRUBAR™ and our commitment to scaling a standout brand in the better-for-you snacking space". About TRUBAR Inc. TRUBAR Inc. is a better-for-you snacking company focused on delivering high-quality, plant-based protein products with exceptional taste and made with clean, recognizable ingredients. TRUBAR™, the Company's signature product line, is distributed through national retailers, club stores, and e-commerce platforms across North America. The Company is focused on expanding TRUBAR's presence throughout North America and select international markets. For more information, visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information Certain statements contained in this news release constitute "forward-looking information" and "forward looking statements" as such terms are used in applicable Canadian securities laws. Forward-looking statements and information are based on plans, expectations and estimates of management at the date the information is provided and are subject to certain factors and assumptions. Specifically, this news release contains forward-looking statements relating the anticipated timing and completion of a distribution of the net proceeds of the Transaction to shareholders of NO BS LIFE, LLC. Forward-looking statements and information are subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking statements and information. Factors that could cause the forward-looking statements and information in this news release to change or to be inaccurate include, but are not limited to, the risks set forth in the Company's management's discussion and analysis available under the Company's SEDAR+ profile at The above summary of assumptions and risks related to forward-looking statements in this news release has been provided to provide shareholders and potential investors with a more complete perspective on the Company's current and future operations and such information may not be appropriate for other purposes. There is no representation by the Company that actual results achieved will be the same in whole or in part as those referenced in the forward-looking statements and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.
